We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+11.18%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$900M
AUM Growth
-$66.1M
Cap. Flow
-$123M
Cap. Flow %
-13.72%
Top 10 Hldgs %
42.92%
Holding
115
New
38
Increased
27
Reduced
28
Closed
14

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$34.5M
2
UTHR icon
United Therapeutics
UTHR
+$23.6M
3
HUM icon
Humana
HUM
+$19.6M
4
SKIN icon
SkinHealth Systems
SKIN
+$14.5M
5
MCRB icon
Seres Therapeutics
MCRB
+$11.1M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$51.8M
2
EXAS
Exact Sciences
EXAS
+$30.2M
3
SNN icon
Smith & Nephew
SNN
+$14.9M
4
SIBN icon
SI-BONE Inc
SIBN
+$10.6M
5
ACLX
Arcellx
ACLX
+$9.41M

Sector Composition

Rank Sector Weight
1 Healthcare 96.82%
2 Consumer Staples 2.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
51
Syndax Pharmaceuticals
SNDX
$1.73B
$4.45M 0.49%
212,600
-110,000
-34% -$2.29M
ETNB
52
DELISTED
89bio
ETNB
$4.29M 0.48%
226,500
-267,500
-54% -$4.7M
DXCM icon
53
DexCom
DXCM
$32.8B
$4.24M 0.47%
+33,000
New +$3.99M
WGS icon
54
GeneDx Holdings
WGS
$1.98B
$4.24M 0.47%
711,396
+167,760
+31% +$1.33M
CBAY
55
DELISTED
Cymabay Therapeutics
CBAY
$4.08M 0.45%
+373,000
New +$3.47M
FDMT icon
56
4D Molecular Therapeutics
FDMT
$535M
$3.96M 0.44%
219,148
-250,252
-53% -$4.61M
VSTM icon
57
Verastem
VSTM
$505M
$3.87M 0.43%
+520,369
New +$3.61M
DICE
58
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$3.72M 0.41%
80,000
-93,447
-54% -$3.23M
NSPR icon
59
InspireMD
NSPR
$33.7M
$3.46M 0.38%
+1,378,128
New +$2.19M
IMVT icon
60
Immunovant
IMVT
$8.05B
$3.29M 0.37%
+173,599
New +$3.24M
TWST icon
61
Twist Bioscience
TWST
$6.19B
$3.27M 0.36%
+160,000
New +$2.4M
KRTX
62
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$3.07M 0.34%
14,140
-19,600
-58% -$4.2M
KROS icon
63
Keros Therapeutics
KROS
$204M
$2.84M 0.32%
70,800
-51,516
-42% -$2.26M
AMLX icon
64
Amylyx Pharmaceuticals
AMLX
$2.37B
$2.59M 0.29%
120,000
+56,786
+90% +$1.53M
XENE icon
65
Xenon Pharmaceuticals
XENE
$6.11B
$2.54M 0.28%
+66,000
New +$2.62M
DMRA
66
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.8B
$2.52M 0.28%
+40,000
New +$2.18M
VCEL icon
67
Vericel Corp
VCEL
$2.35B
$2.52M 0.28%
67,049
-259,400
-79% -$8.53M
LYRA
68
DELISTED
LYRA THERAPEUTICS INC
LYRA
$2.43M 0.27%
11,848
– –
PRAX icon
69
Praxis Precision Medicines
PRAX
$8.58B
$2.42M 0.27%
+140,000
New +$2.14M
CRSP icon
70
CRISPR Therapeutics
CRSP
$5.05B
$2.38M 0.26%
+42,400
New +$2.41M
WHWK
71
Whitehawk Therapeutics
WHWK
$201M
$2.28M 0.25%
+333,227
New +$2.59M
BDTX icon
72
Black Diamond Therapeutics
BDTX
$103M
$2.2M 0.24%
+435,000
New +$888K
ANNX icon
73
Annexon
ANNX
$873M
$2.18M 0.24%
620,400
-295,000
-32% -$1.29M
INSP icon
74
Inspire Medical Systems
INSP
$1.79B
$2.18M 0.24%
6,700
-8,900
-57% -$2.54M
LLY icon
75
Eli Lilly
LLY
$1T
$2.02M 0.22%
+4,300
New +$1.8M
1 2
3
4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, Soleus Capital Management held 115 positions worth $900M, down 6.9% from $966M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Soleus Capital Management withdrew a net $123M in Q2 2023, closing 14 positions and reducing 28 holdings. Its most notable exit was IVERIC bio, Inc. Common Stock, an estimated $51.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 81% a quarter earlier, followed by Consumer Staples.

Against the trend, Soleus Capital Management opened a new position in Teva Pharmaceuticals worth $32M.

  • Soleus Capital Management's largest Q2 2023 buy was Teva Pharmaceuticals: 4,250,000 shares worth $32M.
  • Soleus Capital Management added most to United Therapeutics in Q2 2023, an estimated $23.6M increase.
  • Soleus Capital Management's biggest Q2 2023 reduction was Exact Sciences, cutting an estimated $30.2M.
  • Soleus Capital Management fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $51.8M.
  • Soleus Capital Management's ten largest holdings make up 43% of its $900M portfolio in Q2 2023.
  • Soleus Capital Management opened 38 new positions and closed 14 in Q2 2023.
  • Soleus Capital Management's portfolio value fell 6.9% quarter-over-quarter to $900M.

Based on Soleus Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.